Literature DB >> 25957910

Local Vasogenic Edema without Cerebral Hyperperfusion after Direct Revascularization Surgery for Moyamoya Disease.

Hiroyuki Sakata1, Miki Fujimura2, Shunji Mugikura3, Kenichi Sato1, Teiji Tominaga1.   

Abstract

Superficial temporal artery-middle cerebral artery anastomosis is generally used as the standard surgical treatment for moyamoya disease to prevent cerebral ischemic attacks. Although the main potential complications associated with this treatment are cerebral hyperperfusion and ischemia, the adverse impacts of revascularization surgery remain unclear. Of the 142 consecutive surgeries for moyamoya disease at our hospital from 2008, we herein presented 2 cases of adult-onset moyamoya disease that manifested local vasogenic edema at the site of anastomosis without cerebral hyperperfusion; 1 in a 31-year-old woman presented with transient ischemic attack and the other in a 22-year-old man manifested as minor completed stroke. Both patients underwent superficial temporal artery-middle cerebral artery anastomosis, resulting in the formation of a reversible high-signal-intensity lesion at the site of anastomosis on T2-weighted images along with an increase in apparent diffusion coefficient values, whereas diffusion-weighted images showed no changes. Neither hyperperfusion nor hypoperfusion, as assessed by single-photon emission computed tomography with N-isopropyl[123I]-p-iodoamphetamine, was observed postoperatively. In light of the increased risk of the further progression of vasogenic edema to intracerebral hemorrhage, these patients were treated with prophylactic blood pressure lowering and the intravenous infusion of a free radical scavenger. They did not have any further cerebrovascular events during the follow-up period. Regional vasogenic edema without cerebral hyperperfusion, possibly due to cerebral ischemia/reperfusion injury, may be another novel entity that needs to be considered as a potential complication after extracranial-intracranial bypass for moyamoya disease. Strict postoperative management should be used to avoid hemorrhagic transformation.
Copyright © 2015 National Stroke Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Moyamoya disease; cerebral hyperperfusion; extracranial–intracranial bypass; reperfusion; vasogenic edema

Mesh:

Substances:

Year:  2015        PMID: 25957910     DOI: 10.1016/j.jstrokecerebrovasdis.2015.03.050

Source DB:  PubMed          Journal:  J Stroke Cerebrovasc Dis        ISSN: 1052-3057            Impact factor:   2.136


  4 in total

1.  Intra-operative hemorrhage due to hyperperfusion during direct revascularization surgery in an adult patient with moyamoya disease: a case report.

Authors:  Hiroki Uchida; Hidenori Endo; Miki Fujimura; Toshiki Endo; Kuniyasu Niizuma; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2017-06-09       Impact factor: 3.042

2.  Paradoxical association of symptomatic cerebral edema with local hypoperfusion caused by the 'watershed shift' after revascularization surgery for adult moyamoya disease: a case report.

Authors:  Jin Yu; Miao Hu; Lei Yi; Keyao Zhou; Jianjian Zhang; Jincao Chen
Journal:  Ther Adv Neurol Disord       Date:  2019-09-25       Impact factor: 6.570

3.  Paradoxical symptomatic cerebral blood flow decreases after combined revascularization surgery for patients with pediatric moyamoya disease: illustrative case.

Authors:  Yoshio Araki; Kinya Yokoyama; Kenji Uda; Fumiaki Kanamori; Michihiro Kurimoto; Yoshiki Shiba; Takashi Mamiya; Kai Takayanagi; Kazuki Ishii; Masahiro Nishihori; Kazuhito Takeuchi; Kuniaki Tanahashi; Yuichi Nagata; Yusuke Nishimura; Sho Okamoto; Masaki Sumitomo; Takashi Izumi; Ryuta Saito
Journal:  J Neurosurg Case Lessons       Date:  2022-01-17

Review 4.  Severe cerebral edema induced by watershed shift after bypass in a patient with chronic steno-occlusive disease: a case report and short literature review.

Authors:  Yin Li; Yu-Yu Wei; Yang Cao; Xiao-Yang Lu; Yuan Yao; Lin Wang
Journal:  BMC Neurol       Date:  2020-09-05       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.